HIV-infected youth receiving highly active antiretroviral therapy with low-level viremia and a trend toward increasing viral load are at increased risk for virologic failure, according to research published in the Journal of the Pediatrics Infectious Disease Society.
A retrospective chart review of HIV-infected youth with viral loads between the lower limits of detection of 20 to 75 copies/mL and 1000 copies/mL was used to define patients with low-level viremia. These patients were then observed for at least 24 months of consecutive follow-up. A total of 100 patients were included for analysis. Virologic failure was determined to be 3 or more consecutive plasma viral load levels greater than 1000 copies/mL.
Fifteen patients experienced virologic failure, and the results of logistical regression and receiver operator characteristic curves identified that higher log10 mean viral load, positive slope of the viral load (log10 copies/mL/d), and fewer clinic visits were associated with a higher probability of virologic failure.
Aside from self-reported data on drug adherence, the investigators had no reliable means of assessing adherence to treatment. Questions also remain about the applicability of these results to other groups of perinatally infected youth in other urban centers due to the definitions of virologic failure and viral load used here.
The investigators believe that nonadherence is a major factor contributing to virologic failure among adolescents and “given the recurring nature of poor medication compliance in our population and similar experiences in other centers caring for HIV-affected youth, further research on adherence and how to reliably measure it and how to improve is increasingly becoming a major research priority.” They further recommend “that clinicians should keep a close eye on patients who tend to miss clinical appointments and show an elevated and increasing [viral load].”
Pereira R, Ludwig DA, Mathew S, et al. Predicting viral failure in human immunodeficiency virus perinatally infected youth with persistent low-level viremia on highly active antiretroviral therapy [published online May 19, 2018]. J Pediatric Infect Dis Soc. doi: https://doi.org/10.1093/jpids/piy041